ESPR Esperion Therapeutics, Inc.

40.40
+1  (4%)
Previous Close 39.01
Open 39.15
Price To book 3.85
Market Cap 911.22M
Shares 22,555,000
Volume 3,085,800
Short Ratio 3.35
Av. Daily Volume 1,944,180

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced March 7, 2017. Data due 4Q 2017.
Bempedoic Acid/ Ezetimibe/ Atorvastatin (1002-038)
Hypercholesterolemia
Phase 2 (PK/PD) top-line data met primary endpoint - October 2016.
Bempedoic acid (ETC-1002-035)
Patients treated with high-dose statin therapy
Phase 3 initiation of efficacy trials announced January 8, 2017. Data due mid 2018.
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048
Hypercholesterolemia - statin intolerance
Phase 3 long-term safety and tolerability trial initiated January 2016. Completion of enrollment announced January 25, 2017. Top-line results due 2Q 2018.
Bempedoic acid (ETC-1002-040)
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 2 data released July 2015
Bempedoic acid ETC-1002-014
Hypercholesterolemia and hypertension

Latest News

  1. 3 Hot Biotech Stocks Now
  2. Company News for March 21, 2017
  3. Biotech Premarket Movers: Esperion, Minerva and BioCryst
  4. The Difference Between Spectacular News and No News
  5. Esperion Therapeutics Inc (ESPR): Get It While It’s Cheap
  6. After-hours buzz: ESPR, NKTR, MMSI & more
  7. Here's What Pushed Esperion Therapeutics Inc Stock Higher Today
  8. Esperion And Medicines Co. Recover From Amgen-Induced Pitfall
  9. How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More
  10. Nektar, AMD, Esperion, and More: Here’s Why These Five Stocks Are Surging
  11. Esperion Gets FDA Nod for Cholesterol Drug Program
  12. Esperion Therapeutics stock surges 52% after it says the FDA gave its drug program positive feedback
  13. Monday’s Top Biopharma Movers
  14. Esperion Therapeutics upgraded by Credit Suisse
  15. Biotech Premarket Movers: CytomX, Aevi, Esperion
  16. ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  17. Esperion Therapeutics Sees Clear FDA Path For Its Heart Drug
  18. Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid
  19. Esperion's Dive On Amgen Heart Study 'Counterintuitive' On Pricing
  20. Amgen Tanks On Heart Study; Shares Of Other Drugmakers Tumble